• Contact Us

Columbia University
Irving Medical Center
Neurological Institute

710 West 168th Street, 3rd floor
(212) 305-1818

Clinical Trials

Clinical Trials Currently Recruiting (August 2026)

Mild Cognitive Impairment/Early Onset Alzheimer’s Disease: Focused UltraSound (NIA)
Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound
ClinicalTrials.gov ID NCT06600880.
Phase 1B. Duration:5 visits.
Amnestic Mild Cognitive Impairment/Alzheimer’s Disease. MMSE: 12-26. Age: ≥50.
Procedures include: MRI, Amyloid PET scan, Tau PET Scan, focused ultrasound treatment
(Dr. McIlvain/Dr. Honig/Dr. Konofagou) Call Sergio Jimenez-Gambin 212-342-1612

UPCOMING: Progressive Supranuclear Palsy- (PSP)
A study of NIO752 in patients with Progressive Supranuclear Palsy (PSP)
ClinicalTrials.gov ID NCT07498426. Sponsor: Novartis Pharma AG
Phase 3. Drug is administered by lumbar puncture every 12 weeks over 72 weeks.
Duration: 72 weeks and an optional 96-week open label extension. Eligibility: PSP-RS, symptoms < 5 years, age: 41-81years. PSPRS <40, MMSE ≥ 20.
Procedures include: blood draws, LPs and MRIs
(Dr. Honig) Call Katrina Cuasay 212-305-2077

UPCOMING: Progressive Supranuclear Palsy- (PSP). PSP Clinical Trial Platform (PTP)
A study to evaluate multiple investigational products simultaneously or sequentially in mild-to-moderate PSP
ClinicalTrials.gov ID NCT07173803. Sponsor: National Institute of Aging (NIA), University of California San Francisco (UCSF)
Phase 2. Duration: 52 weeks and an optional open label extension of 12 months.
Eligibility: PSP-RS, symptoms ≤ 5 years. Age: 41-86 MMSE >25
Procedures include: blood draws, MRIs optional LP, optional Skin Biopsy sub-studies.
(Dr. Honig) Call Katrina Cuasay 212-305-2077

Creutzfeldt Jakob Disease (CJD) PRiSM
An Open Label Study of the Safety and Pharmacology of PrP-siRNA in Prion Disease (CJD)
ClinicalTrials.gov ID NCT07444580. Sponsor: NIH/NINDS/NeuroNext.
Phase 1 Treatment (Arm 2) and Observational (Arm 1). Maximum duration approximately 24 weeks.
Eligibility: diagnosed with symptomatic prion disease, Age: ≥18, MRC-PDRS score≥15.
Procedures include: lumbar puncture (LP) and single dose drug administration, follow up LPs, Blood draws, and MRI.
(Dr. Honig) Call Katrina Cuasay 212-305-2077

Early Age-Related Hearing Loss Investigation: EARHLI, (NIH/NIA)
A study to determine the effect of hearing intervention vs. health education comparator intervention on cognitive performance, social engagement, and brain organization/connectivity in adults with Amnestic MCI and Hearing Loss.
ClinicalTrials.gov ID NCT06174038.
Phase 2: Hearing Aid vs. Health Education Comparator, Duration: 52 weeks.
Subjective Cognitive Complaint /Amnestic MCI, Borderline to Moderate Hearing Loss CDR memory score: 0.5. Age: 55 - 75 years. Participants get free hearing aids by the study end.
Procedures include: Hearing test, MRI (half the participants) blood test: pTau, APOE.
(Dr. Justin Golub) Call Jesus Lopez 646-317-3252, email: earhli@cumc.columbia.edu

Mild Cognitive Impairment (COGIT-2 Trial)
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial.
ClinicalTrials.gov ID NCT06601933.
A study comparison of 4 crossword puzzles per week (high dose arm), 1 crossword puzzle per week (low dose arm), or health education.
MCI. MOCA score ≥ 20. Age: 55 to 89 years old. Duration: 78 weeks, 5 in person visits. Procedures: Blood draws, MRIs. Anti-amyloid therapies are not permitted during the study.
(Dr. Devanand) Call: Ian Horton, 646-774-6739 email: ihh2107@cumc.columbia.edu OR Lola Nedic: 646-774-7202 email: ln2563@cumc.columbia.edu

UPCOMING: Pre-Clinical Alzheimer’s Disease (PrevenTRON)
A study of trontinemab in cognitively unimpaired individuals at risk for progression to symptomatic Alzheimer’s Disease.
ClinicalTrials.gov ID NCT07717411. Sponsor: F. Hoffmann-La Roche Ltd
Phase 3: IV infusion every 4 weeks for 24 weeks (Treatment Year 1) followed by every 24 weeks (Treatment Years 2-6)  Eligibility: MMSE: ≥ 27, CDR =0, Age: 55-80. Duration: 4-6 years.
Procedures include:plasma biomarker, amyloid PET or LP, MRIs, optional Tau PET
(Dr. Honig) Call Katrina Causay 212-305-2077

Observational Studies Currently Recruiting (August 2026)

Mild Cognitive Impairment/Alzheimer’s Disease/ Normal Cognition: ADRC clinical core (NIH/NIA)
Alzheimer’s Disease Research Center Clinical Core
Duration: 2 hours visit (in person). Visits are every year for the duration of the study.
Mild Cognitive Impairment/Mild Alzheimer’s Disease/Normal Cognition. Age: 55-90.
Procedures include: MRI, LP.
(Dr. Noble) Call Naara Ramirez Estevez 212-305-9971

Mild Cognitive Impairment/Alzheimer’s Disease/ Normal Cognition: ADRC PET Component (NIH/NIA)
Alzheimer’s Disease Research Center PET Component
Duration: 2-3 visits over 6 months
Mild Cognitive Impairment/Mild Alzheimer’s Disease/Normal Cognition; Age: ≥ 50; must be enrolled in the ADRC
Procedures include: Amyloid and Tau PET scans
(Dr. Lao) Call Hannah Houlihan 212-305-7450

Mild Cognitive Impairment/Alzheimer’s Disease/ Normal Cognition: CLARiTI (NIH/NIA)
ADRC Consortium for Clarity in ADRD Research Through Imaging
Duration: 2 years, baseline visits and 2 year follow up.
CDR 0, 0.5, or 1; Age: ≥ 50; must co-enroll with ADRC
Procedures include: Blood draw, MRI, Amyloid, and Tau PET scans; optional FDG PET scan for those CDR 0.5 or 1
(Dr. Lao) Call Hannah Houlihan 212 305-7450

Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)
(NIA)
ClinicalTrials.gov ID NCT05617014.
Duration: 5 years. Age: 55-90 years, Mild Cognitive Impairment, AD.
MMSE: 20-30, CDR: 0.5-1.0 Procedures: MRI, amyloid PET, Tau PET, optional LP. Anti amyloid therapies permitted.
(Dr. Honig) Call Jee Min Kim 212 305- 5805 or Katrina Causay 212 305-2077

UPCOMING: Mild Cognitive Impairment/Early Onset Alzheimer’s Disease/Normal Cognition: LEADS (NIH/NIA)
Longitudinal Early Onset Alzheimer’s Disease Study
ClinicalTrials.gov ID NCT03507257.
Duration: 4 years, yearly visit. Mild Cognitive Impairment/Early Onset Alzheimer’s Disease. CDR: 0.5 or 1.0. Age: 40-64.
Procedures include MRI, Amyloid PET, Tau PET, optional LP. Optional genetic results. Anti amyloid therapies permitted.
(Dr. Honig) Call Arlene Mejia 212-305-9168

Amnestic, visual, and language variants of Mild Cognitive Impairment/AD: ADVISe (NIH/NIA)
Longitudinal imaging of microglial activation in different clinical variants of Alzheimer's disease
ClinicalTrials.gov ID NCT04576793.
Duration: 2 years, baseline visits and 2 year follow up. Amnestic Mild Cognitive Impairment/Amnestic Alzheimer's Disease/Posterior Cortical Atrophy/Logopenic Variant Primary
Progressive Aphasia/Normal Cognition. CDR 0, 0.5 or 1.0. Age: 50+.
Procedures include: MRI, Amyloid, Tau, and Inflammation PET scans, LP.
(Dr. Small/Noble) Call Hannah Houlihan 212 305-7450

Alzheimer’s Disease: EFIGA (NIH/NIA)
Genetic Study of Alzheimer’s Disease in Caribbean Hispanics
Duration: 1.5 hours visit (in person). Visits are every 2 years for the duration of the study. Hispanic individuals or families with or without memory problems willing to participate. Age: Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Angel Piriz 212-305-2309

Alzheimer’s Disease: AD Family Based Study (FBS) (NIH/NIA)
Late and Early Onset Alzheimer’s Disease
Duration: 1.5 hours visit (in person/over the phone). Every 2 years visit for the duration of the study. Any ethnic background families with AD family history and/or with multiple affected alive members willing to participate.
Age: Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Pamela Del Rosario 212-304-7284, email: pd2727@cumc.columbia.edu.

Alzheimer’s Disease: DAWN (NIH/NIA)
Genetic Study of Alzheimer’s Disease in Hispanics and African Americans.
Duration: 1.5 hours visit (in person/over the phone).
Hispanic or African American individuals with and without memory problems.
Age: Affected and Unaffected 60 or older
(Dr. Reitz) Call Jenny Chavez 212-342-3029 jc5835@cumc.columbia.edu
(Dr. Tosto) Call Jose Saint-Hilaire 646-317-9317 email: jls2403@cumc.columbia.edu

Alzheimer’s in African American Families (NIH/NIA)
Recruiting African American families with at least one with cognitive impairment plus another family member willing to participate.
Duration: 1.5 hours visit (in person/over the phone).
Every 2 years visit for the duration of the study.
Age: Affected any age. Unaffected 50 or older.
(Dr. Reitz ) Call Jenny Chavez 212-342-3029

Alzheimer’s Disease: Asian Cohort Alzheimer’s Disease (ACAD) (NIH/NIA)
Late Onset Alzheimer’s Disease
Duration: 2 hours visit (in person/over the phone). Every 2 years visit for the duration of the study. Chinese, Korean or Vietnamese individuals with AD family history with or without memory problems willing to participate.
Age: Affected 60 and older.
(Dr. Mayeux) Call Fangcong (Nini) Cheng: 332-257-4055

Frontotemporal Dementia: ALLFTD (NIH/NIA/NINDS)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration Protocol
ClinicalTrials.gov ID NCT04363684.
Duration: 3-6 hour visits, for 1-5 years. National consortium enrolling: Behavioral Variant Frontotemporal Dementia/Non-Fluent Variant Primary Progressive Aphasia/Semantic Variant Primary Progressive Aphasia/ Frontotemporal Dementia-Amyotrophic Lateral Sclerosis.
Also enrolling asymptomatic members of families with mutation in MAPT, GRN, C9orf72, or strong family history of FTLD.
Age: ≥18, CDR 0, 0.5, 1, or 2.
Procedures include: MRI, optional LP, optional genetic testing.
(Dr. Honig) Call Andrea Farah 212 305-2371

Programs Currently Recruiting (August 2026)

GUIDE (Guiding an Improved Dementia Experience) Model Program
A Medicare-funded care coordination program for patients with dementia and their caregivers
The GUIDE model is a comprehensive, coordinated dementia care and aims to improve quality of life for people with dementia, reduce strain on their unpaid caregivers, and enable people with dementia to remain in their homes and communities. The GUIDE Model will also enhance access to the support and resources that caregivers need, including education, training and respite services.
Eligibility: must have a dementia diagnosis and CDR: 1 or greater; must have Original Medicare Part A and Part B (no Medicare Advantage plans, Special Needs Plans, or PACE programs); reside in any zip code in the 5 boroughs of New York City or Westchester County, has not elected the Medicare hospice benefit; and is not a long-term nursing home resident.
Contact social worker Julie Tellez, LMSW | GUIDE Patient Care Navigator email: jat2239@cumc.columbia.edu 212-305-2387

Arts and Minds
The Studio Museum in Harlem, New York Historical Society, and El Museo del Barrio
Excluded: persons with depression (only), cognitively normal persons, and patients with dementia. Spanish-speakers are welcome.
Participants will explore the world of art and culture in these interactive 75-minute programs.
(Dr. Noble) Call Carolyn Halpin-Healy 646-755-3726

A Friend for Rachel
A companionship program
MCI, early AD, early PPA, FTD (if not too behavioral), early DLB (if no hallucinations). Must be mobile and able to go out without an aide.
Participants will spend a few hours a week with their student friend either exploring NYC or staying near home.
Contact Jill Goldman email: jg2673@cumc.columbia.edu